Use of an individual-based model of pneumococcal carriage for planning a randomized trial of a vaccine

Abstract

For encapsulated bacteria such as Streptococcus pneumoniae, asymptomatic carriage is more common and longer in duration than disease, and hence is often a more convenient endpoint for clinical trials of vaccines against these bacteria. However, using a carriage endpoint entails specific challenges. Carriage is almost always measured as prevalence, whereas the vaccine may act by reducing incidence or duration. Thus, to determine sample size requirements, its impact on prevalence must first be estimated. The relationship between incidence and prevalence (or duration and prevalence) is convex, saturating at 100% prevalence. For this reason, the proportional effect of a vaccine on prevalence is typically less than its proportional effect on incidence or duration. This relationship is further complicated in the presence of multiple pathogen strains. In addition, host immunity to carriage accumulates rapidly with frequent exposures in early years of life, creating potentially complex interactions with the vaccines effect. We conducted a simulation study to predict the impact of an inactivated whole cell pneumococcal vaccine--believed to reduce carriage duration--on carriage prevalence in different age groups and trial settings. We used an individual-based model of pneumococcal carriage that incorporates relevant immunological processes, both vaccine-induced and naturally acquired. Our simulations showed that for a wide range of vaccine efficacies, sampling time and age at vaccination are important determinants of sample size. There is a window of favorable sampling times during which the required sample size is relatively low, and this window is prolonged with a younger age at vaccination, and in a trial setting with lower transmission intensity. These results illustrate the ability of simulation studies to inform the planning of vaccine trials with carriage endpoints, and the methods we present here can be applied to trials evaluating other pneumococcal vaccine candidates or comparing alternative dosing schedules for the existing conjugate vaccines.\n\nAuthor SummaryStreptococcus pneumoniae, a bacterium carried in the nasopharynx of many healthy people, is also a leading cause of bacterial pneumonia, sepsis, and ear infections in children aged five years and younger. Vaccines targeting select strains of S. pneumoniae have been effective, and the development of new vaccines, particularly those that target all strains, can further lower disease burden. For clinical trials of these vaccines, the number of study participants needed depends on the expected effect of the vaccine on a conveniently measured outcome: asymptomatic carriage. The most economical way to test a vaccine for its effect on carriage is by measuring prevalence at a specific time, and comparing vaccinated to unvaccinated participants. The relationship between incidence (or duration) and prevalence is complex, and changes with time as children develop natural immunity. We explored this relationship using a mathematical model. Given a vaccine efficacy, our computer simulations predict that fewer study participants are needed if they are vaccinated at a younger age, taken from a population with intermediate levels of transmission, and sampled for carriage at a certain time window: 9 to 18 months after vaccination. Our study illustrates how simulation studies can help plan more efficient vaccine trials.